A nationally representative survey of 100 US-based healthcare providers managing sickle cell patients found a significant gap between treatment availability and clinical utilization. While 91% of surveyed providers report access to red blood cell exchange—a procedure that removes damaged red blood cells and replaces them with donor cells—fewer than 3% of patients have actually received the treatment.
The research identified multiple barriers preventing wider adoption of the therapy. Coordination challenges between medical departments, limited availability of donated blood, and insufficient provider familiarity with the procedure emerged as the most common obstacles. Only 5% of surveyed healthcare providers reported encountering no barriers to administering the treatment. Among patients, concerns about insurance coverage represented a significant deterrent to accessing red blood cell exchange therapy.
Sickle cell disease affects more than 100,000 people in the United States and 8 million worldwide, with the disease disproportionately impacting communities of color. Of diagnosed patients, 90% are non-Hispanic Black or African American while an estimated 3%-9% are Hispanic or Latino. Experts noted that comprehensive sickle cell disease centers, which bring together hematologists, transfusion specialists, and support services, remain concentrated in limited geographic areas and are inaccessible to many patients in rural communities.
Geographic disparities and socioeconomic factors further complicate patient access. Roughly 80% of sickle cell patients rely on Medicaid, and many live in rural areas with limited access to specialized facilities. Researchers and medical professionals emphasized the need for expanded provider education, growth in dedicated sickle cell centers, and better coordination of care networks to ensure patients can access established treatment guidelines and therapeutic options.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI